{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:49:34Z","timestamp":1785887374858,"version":"3.56.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR-CGS-D"],"award-info":[{"award-number":["CIHR-CGS-D"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neurot.2024.e00498","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:48:32Z","timestamp":1733834912000},"page":"e00498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["PET in neurotherapeutic discovery and development"],"prefix":"10.1016","volume":"22","author":[{"given":"Melissa","family":"Chass\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00498_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00498_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Ferrari","year":"2022","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.neurot.2024.e00498_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for central nervous system disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00498_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1017\/S1461145713000345","article-title":"The current development of CNS drug research","volume":"16","author":"Wegener","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/cn500063v","article-title":"Statistics for global prescription medications: CNS therapeutics maintain a leading position among small molecule therapeutics","volume":"5","author":"Lindsley","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neurot.2024.e00498_bib6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib7","series-title":"Research and m nnnnnnnnnnnnnbevelopment in the pharmaceutical industry","author":"Austin","year":"2021"},{"key":"10.1016\/j.neurot.2024.e00498_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.trechm.2019.04.009","article-title":"Challenges and opportunities in central nervous system drug discovery","volume":"1","author":"Danon","year":"2019","journal-title":"Trends Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.neurot.2024.e00498_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jlcr.4019","article-title":"Strategies for designing novel positron emission tomography (PET) radiotracers to cross the blood\u2013brain barrier","volume":"66","author":"Lindberg","year":"2023","journal-title":"J\u00a0Label Compd Radipharm"},{"key":"10.1016\/j.neurot.2024.e00498_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00498_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00498_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.neurot.2024.e00498_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nrd.2016.184","article-title":"Phase II and phase III failures: 2013\u20132015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00498_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How much does it cost to research and develop a new drug? A systematic review and assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00498_bib16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/jcbfm.2012.1","article-title":"Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs","volume":"32","author":"Gunn","year":"2012","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00498_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-024-01970-8","article-title":"Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective","author":"Etkin","year":"2024","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry's brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2024.e00498_bib19","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"334","author":"Yao","year":"2024","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.neurot.2024.e00498_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.neurot.2024.e00498_bib21","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"4","author":"Wallach","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00498_bib22","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41380-023-02271-0","article-title":"Neuroimaging in psychedelic drug development: past, present, and future","volume":"28","author":"Wall","year":"2023","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.neurot.2024.e00498_bib23","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/molecules26092451","article-title":"Molecular and functional imaging studies of psychedelic drug action in animals and humans","volume":"26","author":"Cumming","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.neurot.2024.e00498_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-010-1686-8","article-title":"Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers","volume":"38","author":"Ettrup","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.neurot.2024.e00498_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neuroimage.2013.08.035","article-title":"Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain","volume":"84","author":"Finnema","year":"2014","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2024.e00498_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroimage.2016.02.001","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test-retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin","volume":"130","author":"Ettrup","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2024.e00498_bib27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","article-title":"Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants","volume":"26","author":"Becker","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced States depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr Biol"},{"key":"10.1016\/j.neurot.2024.e00498_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib31","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurot.2024.e00498_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.07.003","article-title":"Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: relevance for psychedelic research","volume":"88","author":"Holze","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2024.e00498_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-Hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.neurot.2024.e00498_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.yfrne.2010.12.001","article-title":"11\u03b2-Hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress","volume":"32","author":"Wyrwoll","year":"2011","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.neurot.2024.e00498_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150452","article-title":"Imaging brain cortisol regulation in PTSD with a target for 11\u03b2-hydroxysteroid dehydrogenase type 1","volume":"131","author":"Bhatt","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00498_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2024.100609","article-title":"Imaging a putative marker of brain cortisol regulation in alcohol use disorder","volume":"29","author":"Verplaetse","year":"2024","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.neurot.2024.e00498_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-3223(95)00451-3","article-title":"Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis","volume":"40","author":"Yehuda","year":"1996","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.neurot.2024.e00498_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s11307-020-01490-z","article-title":"Body mass index and age effects on brain 11\u03b2-hydroxysteroid dehydrogenase type 1: a positron emission tomography study","volume":"22","author":"Bini","year":"2020","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.neurot.2024.e00498_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cts.12618","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ASP3662, a novel 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, in healthy young and elderly subjects","volume":"12","author":"Bellaire","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.neurot.2024.e00498_bib40","article-title":"Radiosynthesis and evaluation of an 11-\u03b2 hydroxy- steroid dehydrogenase-1 (11\u03b2-HSD1) PET ligand in rhesus monkey","volume":"54","author":"Wenping","year":"2011","journal-title":"J\u00a0Label Compd Radiopharm"},{"key":"10.1016\/j.neurot.2024.e00498_bib41","first-page":"1050","article-title":"Discovery of a novel radioligand [11C]AS2471907 for PET imaging of the brain 11\u03b2-HSD1","volume":"57","author":"Iwashita","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.neurot.2024.e00498_bib42","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1021\/acschemneuro.8b00715","article-title":"A\u00a0novel 18F-labeled radioligand for positron emission tomography imaging of 11\u03b2-hydroxysteroid dehydrogenase (11\u03b2-HSD1): synthesis and preliminary evaluation in nonhuman primates","volume":"10","author":"Baum","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neurot.2024.e00498_bib43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0271678X19838633","article-title":"First in-human PET study and kinetic evaluation of [18F]AS2471907 for imaging 11\u03b2-hydroxysteroid dehydrogenase type 1","volume":"40","author":"Bhatt","year":"2020","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00498_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00498_bib45","first-page":"315","article-title":"Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"Media Commun"},{"key":"10.1016\/j.neurot.2024.e00498_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2024.e00498_bib47","doi-asserted-by":"crossref","first-page":"9147","DOI":"10.1021\/acs.jmedchem.3c00746","article-title":"Discovery of AZD4747, a potent and selective inhibitor of mutant GTPase KRASG12C with demonstrable CNS penetration","volume":"66","author":"Kettle","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00498_bib48","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1021\/acs.jmedchem.3c02277","article-title":"Identification of novel, selective ataxia-telangiectasia mutated kinase inhibitors with the ability to penetrate the blood\u2013brain barrier: the discovery of AZD1390","volume":"67","author":"Pike","year":"2024","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116781","article-title":"Progress of ATM inhibitors: opportunities and challenges","volume":"277","author":"Du","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00498_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans\u2014a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"issue":"S2","key":"10.1016\/j.neurot.2024.e00498_bib51","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.annonc.2023.09.1699","article-title":"505MO A phase 0\/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients","volume":"34","author":"Sanai","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurot.2024.e00498_bib52","first-page":"2431","article-title":"Activin receptor-like kinases: a diverse family playing an important role in cancer","volume":"6","author":"Loomans","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.neurot.2024.e00498_bib53","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cells8111366","article-title":"ACVR1 function in health and disease","volume":"8","author":"Valer","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2024.e00498_bib54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrclinonc.2014.74","article-title":"ACVR1 mutations\u2014a key piece in paediatric diffuse glioma","volume":"11","author":"Villanueva","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.neurot.2024.e00498_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s42003-019-0420-8","article-title":"ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma","volume":"9","author":"Carvalho","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.neurot.2024.e00498_bib56","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.1021\/acsomega.1c02983","article-title":"Recent advances in ALK2 inhibitors","volume":"6","author":"Rooney","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.neurot.2024.e00498_bib57","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","article-title":"Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Ensan","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib58","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1021\/acs.jmedchem.0c01199","article-title":"Leveraging an open science drug discovery model to develop CNS-penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Smil","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib59","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1021\/acs.jmedchem.3c02308","article-title":"Discovery of conformationally constrained ALK2 inhibitors","volume":"67","author":"Gonz\u00e1lez-\u00c1lvarez","year":"2024","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp8334","article-title":"An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva","volume":"16","author":"Davis","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00498_bib61","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.1021\/acs.jmedchem.4c00629","article-title":"Discovery of two highly selective structurally orthogonal chemical probes for activin receptor-like kinases 1 and 2","volume":"67","author":"N\u011bmec","year":"2024","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00498_bib62","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1021\/acsmedchemlett.1c00127","article-title":"Leveraging open science drug development for PET: preliminary neuroimaging of 11C-labeled ALK2 inhibitors","volume":"12","author":"Murrell","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.neurot.2024.e00498_bib63","article-title":"In vitro and in vivo evaluation of [11C]M4K2127 for PET imaging activin receptor-like kinase 2","volume":"126","author":"Chass\u00e9","year":"2023","journal-title":"Nucl Med Biol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00498_bib64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET radiotracers: crossing the blood-brain barrier and surviving metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neurot.2024.e00498_bib65","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neurot.2024.e00498_bib66","first-page":"199","article-title":"The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS","volume":"1","author":"Bachstetter","year":"2010","journal-title":"Aging Dis"},{"key":"10.1016\/j.neurot.2024.e00498_bib67","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s12035-023-03829-3","article-title":"CNS-active p38\u03b1 MAPK inhibitors for the management of neuroinflammatory diseases: medicinal chemical properties and therapeutic capabilities","volume":"61","author":"Valipour","year":"2024","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00498_bib68","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood.V108.11.3580.3580","article-title":"Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM)","volume":"108","author":"Siegel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.neurot.2024.e00498_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3899\/jrheum.100602","article-title":"A\u00a024-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis","volume":"38","author":"Genovese","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.neurot.2024.e00498_bib70","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/acschemneuro.3c00205","article-title":"Synthesis and preclinical positron emission tomography imaging of the p38 MAPK inhibitor [11C]talmapimod: effects of drug efflux and sex differences","volume":"14","author":"Chass\u00e9","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neurot.2024.e00498_bib71","first-page":"4595","article-title":"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00498_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00498_bib73","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00498_bib74","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00498_bib75","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1002\/alz.13084","article-title":"Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease","volume":"19","author":"Imbimbo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurot.2024.e00498_bib76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nucmedbio.2022.04.001","article-title":"Tracer development for PET imaging of proteinopathies","volume":"114","author":"Kallinen","year":"2022","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.neurot.2024.e00498_bib77","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jalz.2019.02.004","article-title":"A\u00a0new perspective for advanced positron emission tomography\u2013based molecular imaging in neurodegenerative proteinopathies","volume":"15","author":"Perani","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neurot.2024.e00498_bib78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","article-title":"Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions","volume":"14","author":"Villemagne","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2024.e00498_bib79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s44303-024-00032-4","article-title":"Emerging targets for positron emission tomography imaging in proteinopathies","volume":"2","author":"Chass\u00e9","year":"2024","journal-title":"Npj Imaging"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00498_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.62347\/USWK7545","article-title":"In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-\u03b38 and muscarinic M4 receptors in Alzheimer's disease","volume":"14","author":"d'Orchymont","year":"2024","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.neurot.2024.e00498_bib81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2024.e00498_bib82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00498_bib83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00498_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00498_bib85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00498_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A\u00a0randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alz Res Therapy"},{"key":"10.1016\/j.neurot.2024.e00498_bib87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00498_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00498_bib89","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.0000000000001231","article-title":"Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures","volume":"84","author":"Apostolova","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00498_bib90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mcn.2018.12.004","article-title":"Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease","volume":"97","author":"Cohen","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.neurot.2024.e00498_bib91","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2020","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neurot.2024.e00498_bib92","first-page":"469","article-title":"FDA approval for Biogen's aducanumab sparks Alzheimer disease firestorm","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00498_bib93","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00498_bib94","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: rationale and clinical applications","volume":"20","author":"Therriault","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2024.e00498_bib95","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1038\/s41467-024-49258-1","article-title":"Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer\u2019s disease tauopathies","volume":"15","author":"Lindberg","year":"2024","journal-title":"Nat Commun"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:25:33Z","timestamp":1740140733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1878747924001855"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00498","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET in neurotherapeutic discovery and development","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00498"}}